Related Experiment Videos

Protein kinase C beta1 is implicated in the regulation of neuroblastoma cell growth and proliferation

K Svensson1, R Zeidman, U Trollér

  • 1Lund University, Department of Laboratory Medicine, Molecular Medicine, Malmö University Hospital, Sweden.

Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research
|January 10, 2001
PubMed

Insights

Protein kinase C (PKC) betaI supports neuroblastoma cell growth. Inhibiting PKCbeta may enhance chemotherapy effectiveness against neuroblastoma, offering a potential new treatment strategy.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Protein kinase C (PKC) isoforms are implicated in cell proliferation.
  • Neuroblastoma is a pediatric cancer with diverse therapeutic challenges.

Purpose of the Study:

  • To investigate the role of specific PKC isoforms in neuroblastoma cell proliferation.
  • To explore the potential of PKC inhibition as a therapeutic strategy for neuroblastoma.

Main Methods:

  • Transfection of SK-N-BE(2) cells with PKC C2 and V5 domain expression vectors.
  • Assessment of proliferation markers (cyclin A, bromodeoxyuridine incorporation).
  • Treatment with a PKCbeta-specific inhibitor (LY379196) and chemotherapy agents (paclitaxel, vincristine).

Main Results:

  • PKCalpha C2 domain suppressed proliferation markers, suggesting a role for classical PKC isoforms.
  • PKCbetaI V5 fragment most effectively suppressed proliferation and localized to the nucleus.
  • PKCbeta inhibition suppressed neuroblastoma cell growth and enhanced the efficacy of paclitaxel and vincristine.

Conclusions:

  • PKCbetaI positively influences neuroblastoma cell growth and proliferation.
  • PKCbeta inhibition can potentiate the anti-cancer effects of microtubule-targeting agents in neuroblastoma.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...